LDS/Medical Tests/miR Sentinel™ (microRNA) Prostate Cancer Test

miR Sentinel™ (microRNA) Prostate Cancer Test

The miR Sentinel™ Prostate Cancer Test is an advanced, non-invasive molecular diagnostic assay designed to stratify risk and guide biopsy decisions in men suspected of having prostate cancer. Traditional screening approaches, such as serum total prostate-specific antigen (PSA), are limited by low specificity and overlap with benign conditions like BPH, leading to unnecessary biopsies and overdiagnosis. The miR Sentinel test overcomes these challenges by analyzing the expression profile of 442 small non-coding RNAs (sncRNAs) including microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs) extracted from urinary exosomes. These vesicles originate from the tumor microenvironment and reflect the molecular activity of prostate cancer cells.

Utilizing quantitative reverse transcription PCR (RT-qPCR), the test generates a molecular risk score categorized as “No molecular evidence,” “Low,” “Moderate,” or “Elevated” risk for clinically significant prostate cancer. The assay demonstrates high accuracy in identifying patients with high-grade prostate cancer (Gleason ≥ 7) and distinguishing them from those with indolent or benign disease, thus improving patient selection for biopsy, MRI, and definitive therapy.

  • Assists in diagnostic accuracy and reduce unnecessary prostate biopsies
  • Assists in risk stratification for clinically significant prostate cancer
  • Supports decisions for MRI follow-up, biopsy, or active surveillance

Risk is reported as:

  • No molecular evidence of prostate cancer
  • Low Risk
  • Moderate Risk
  • Elevated Risk

Each risk level corresponds to the likelihood of harboring clinically significant prostate cancer and informs clinical decision-making.

Not applicable; results are interpreted via proprietary risk algorithms

Quantitative reverse transcription PCR (RT-qPCR) following isolation of exosomal sncRNAs from urine.

First-catch urine in sterile cup.

Stability

  • Refrigerated: 3-5 days
PSA, prostate biopsy, Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (phi score, 4Kscore®), Serum.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login